REAL-WORLD PATIENT SUCCESSES
REAL-WORLD PATIENT SUCCESSES
EDDIE VAZQUEZ: T1D PATIENT + IRONMANIf you’re looking for an incredibly inspirational story to share with patients—especially those striving to meet exercise goals—look no further than this video about Eddie Vazquez, T1D patient and IRONMAN athlete. With the help of the MiniMed 530G with Enlite to keep his blood sugar levels in check while training for the grueling triathlon’s 2.4-mile swim, 112-mile bike ride, and 26.2-mile run, Eddie is among an elite group of athletes who have completed the IRONMAN. He hopes his success will motivate other people with diabetes to embrace physical activity. He explains: “If I can show them I can complete an IRONMAN being a regular 9 to 5 type guy and that inspires them to just get up and walk, or do a 5K, or do anything in a positive direction towards exercise—that is my No. 1 goal.” "Diabetes is just a disease,” Eddie adds. “I wasn’t going to let it define me."
Hawbaker K. From type 1 diabetes to IronMan: A triathlete’s journey. Medtronic Diabetes. http://www.loop-blog.com/from-type-1-diabetes-to-ironman-a-triathletes-journey. Accessed April 23, 2015.
AN INSIDERS’ LOOK AT OPT2MISE:
HOW PUMP THERAPY CAN BENEFIT T2D PATIENTS WITH POOR GLUCOSE CONTROL DESPITE MDICheck out this exciting new webinar led by Bruce Bode, MD, that gives you insights into OpT2mise, the largest randomized, controlled study on insulin pump therapy for T2D. The international trial compared the efficacy and safety of insulin pump therapy and multiple daily injection (MDI) therapy in 331 adult patients (aged 30 to 75 years) with T2D who had failed to respond to a basal-bolus regimen after active insulin titration [Reznik et al]. As you have likely heard by now—because good news travels fast—OpT2mise found that MiniMed insulin pumps are a “safe and valuable treatment option” in patients with poorly controlled T2D on MDI therapy [Reznik et al]. In the webinar, Dr. Bode—part of the OpT2mise Study Group—explains the study design, the clinical outcomes—and most importantly, what it all means to you and your T2D patients. Some of the trial’s lead investigators share their insights, and Dr. Bode presents a compelling case study. BONUS: You can read more about Op2Tmise in this issue’s From the Experts column by Beth Nardacci, FNP-BC, CDE, one of the trial’s investigators.
professional.medtronicdiabetes.com/webinar. Accessed April 23, 2015. OpT2mise: The largest randomized, controlled study on insulin pump therapy for type 2 diabetes. Medtronic Diabetes. http://professional.medtronicdiabetes.com/opt2mise. Accessed April 23, 2015. Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): A randomized open-label controlled trial. Lancet. 2014; 384:1265-1272.